Accentia Biopharmaceuticals, Inc. · Tampa, FL United States
| 324 S. Hyde Park Ave., Ste. 350 | Phone: 813-864-2554 |
| Tampa, FL | Fax: 813-258-6912 |
| 33606 | |
| United States | 
Map This Company |
Accentia Biopharmaceuticals, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Accentia Biopharmaceuticals is accentuating its positives and eliminating its negatives. The drug development company is focused on two development-stage drugs, multiple sclerosis drug Revimmune and BiovaxID, a possible vaccine for non-Hodgkin's lymphoma being developed by majority-owned subsidiary
Accentia Biopharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | PublicHeadquarters |
|---|---|
| Fiscal Year-End | September |
| 2011 Employees | 68 |
Executives
15 executives listed for Accentia Biopharmaceuticals, Inc.'s Tampa, FL location.
| Chairman and CEO | Francis O'Donnell | |
|---|---|---|
| President and General Counsel | Samuel Duffey | |
| Acting CFO and Controller | Garrison Hasara |